JPWO2021142234A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021142234A5
JPWO2021142234A5 JP2022542364A JP2022542364A JPWO2021142234A5 JP WO2021142234 A5 JPWO2021142234 A5 JP WO2021142234A5 JP 2022542364 A JP2022542364 A JP 2022542364A JP 2022542364 A JP2022542364 A JP 2022542364A JP WO2021142234 A5 JPWO2021142234 A5 JP WO2021142234A5
Authority
JP
Japan
Prior art keywords
seq
cdr
optionally
oligonucleotide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542364A
Other languages
English (en)
Japanese (ja)
Other versions
JP7829488B2 (ja
JP2023509793A (ja
JP2023509793A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012667 external-priority patent/WO2021142234A1/en
Publication of JP2023509793A publication Critical patent/JP2023509793A/ja
Publication of JPWO2021142234A5 publication Critical patent/JPWO2021142234A5/ja
Publication of JP2023509793A5 publication Critical patent/JP2023509793A5/ja
Application granted granted Critical
Publication of JP7829488B2 publication Critical patent/JP7829488B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542364A 2020-01-10 2021-01-08 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 Active JP7829488B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202062959776P 2020-01-10 2020-01-10
US62/959,776 2020-01-10
US202062965712P 2020-01-24 2020-01-24
US62/965,712 2020-01-24
US202062968383P 2020-01-31 2020-01-31
US62/968,383 2020-01-31
US202063055499P 2020-07-23 2020-07-23
US63/055,499 2020-07-23
US202063069063P 2020-08-23 2020-08-23
US63/069,063 2020-08-23
US202063132856P 2020-12-31 2020-12-31
US63/132,856 2020-12-31
PCT/US2021/012667 WO2021142234A1 (en) 2020-01-10 2021-01-08 Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Publications (4)

Publication Number Publication Date
JP2023509793A JP2023509793A (ja) 2023-03-09
JPWO2021142234A5 true JPWO2021142234A5 (https=) 2024-01-17
JP2023509793A5 JP2023509793A5 (https=) 2024-01-17
JP7829488B2 JP7829488B2 (ja) 2026-03-13

Family

ID=76788870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542364A Active JP7829488B2 (ja) 2020-01-10 2021-01-08 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用

Country Status (11)

Country Link
US (1) US20230144436A1 (https=)
EP (1) EP4087653A4 (https=)
JP (1) JP7829488B2 (https=)
KR (1) KR20220125800A (https=)
CN (1) CN115427108A (https=)
AU (1) AU2021206234A1 (https=)
BR (1) BR112022013686A2 (https=)
CA (1) CA3163295A1 (https=)
IL (1) IL294479A (https=)
MX (1) MX2022008533A (https=)
WO (1) WO2021142234A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
JP7780691B2 (ja) * 2020-01-10 2025-12-05 ダイン セラピューティクス,インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
US20240117356A1 (en) * 2020-12-31 2024-04-11 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP4396352A4 (en) * 2021-09-01 2025-10-01 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS FOR REDUCING DMPK EXPRESSION
EP4396231A1 (en) 2021-09-01 2024-07-10 Biogen MA Inc. Anti-transferrin receptor antibodies and uses thereof
IL311507A (en) * 2021-09-16 2024-05-01 Dyne Therapeutics Inc Dosing of muscle targeting complexes for the treatment of dystrophinopathy
KR20240099448A (ko) * 2021-11-12 2024-06-28 다인 세라퓨틱스, 인크. 안면견갑상완 근육 이영양증을 치료하기 위한 근육 표적화 복합체
US20250339553A1 (en) * 2022-04-15 2025-11-06 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2024257848A1 (ja) * 2023-06-16 2024-12-19 ルクサナバイオテク株式会社 遅発性中枢毒性が低減されているアンチセンスオリゴヌクレオチドの設計方法、及びその製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60312639T2 (de) * 2002-01-18 2007-11-29 Pierre Fabre Médicament Antikörper gegen igf-ir und ihre verwendungen
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
PE20190658A1 (es) * 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
US9610362B2 (en) * 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
CA2889788A1 (en) * 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EP3353306A4 (en) * 2015-09-25 2019-06-05 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
CN109310765A (zh) * 2016-06-20 2019-02-05 领先基因生物技术股份有限公司 抗体-药物偶联物
TWI761413B (zh) * 2016-12-26 2022-04-21 日商Jcr製藥股份有限公司 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
JP7506601B2 (ja) * 2017-12-06 2024-06-26 アビディティー バイオサイエンシーズ,インク. 筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
JP7576542B2 (ja) * 2018-08-02 2024-10-31 ダイン セラピューティクス,インコーポレーテッド 筋標的化複合体およびそれらの使用
CA3163283A1 (en) * 2020-01-10 2021-07-15 Romesh R. Subramanian Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
WO2021142313A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
KR20220125801A (ko) * 2020-01-10 2022-09-14 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
JP7780691B2 (ja) * 2020-01-10 2025-12-05 ダイン セラピューティクス,インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
WO2021150382A1 (en) * 2020-01-24 2021-07-29 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof in treating muscle atrophy
CN115427059A (zh) * 2020-01-31 2022-12-02 达因疗法公司 抗转铁蛋白受体(tfr)抗体及其用途

Similar Documents

Publication Publication Date Title
JPWO2021142234A5 (https=)
JPWO2021142313A5 (https=)
JPWO2021142307A5 (https=)
JPWO2021142275A5 (https=)
JP2025067909A5 (https=)
IL315944A (en) Muscle targeting complexes and uses thereof for treating myotonic dystrophy
IL309910A (en) Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
IL316143A (en) Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
IL317871A (en) Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy
JPWO2021142227A5 (https=)
JPWO2022026152A5 (https=)
JP2021533199A5 (https=)
JP2021533200A5 (https=)
IL312170A (en) Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy
CA3226307A1 (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL316206A (en) Dosage of muscle targeting complexes for the treatment of myotonic dystrophy
IL309937A (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL309936A (en) Muscle targeting complexes and formulations for the treatment of dystrophinopathy
JP2021533197A5 (https=)
IL309911A (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
JPWO2022020107A5 (https=)
JPWO2020132584A5 (https=)
JPWO2018129384A5 (https=)
JPWO2020028832A5 (https=)
JPWO2020028864A5 (https=)